TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01131507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008)
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
Study: NCT01977547

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Short storage RBC age
Description: IND obtained to cover the expiration date on the red blood cell unit

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Short storage RBC age
Description: IND obtained to cover the expiration date on the red blood cell unit
Study: NCT00144807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Study: NCT02130817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus withdrawal
Description: Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis/Intravenous Immunoglobulin G
Description: Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (ATG)
Description: Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
Study: NCT00992108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: 1cc 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemodenervation
Description: botulinum toxin
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet
Study: NCT03902431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABCS training
Description: Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
Study: NCT03916770

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vibrator
Description: The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real vibrator
Description: The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
Study: NCT00593216

Intervention type: DEVICE
Intervention: Functional MRI imaging
Description: The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.

Intervention type: DEVICE
Intervention: Functional MRI imaging
Description: The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
Study: NCT02208310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10,000 IU
Description: Cholecalciferol 10,000 IU po daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 400 IU
Description: Cholecalciferol 400 IU po daily
Study: NCT04424095

Intervention type: DIAGNOSTIC_TEST
Intervention: In-office vascular visit
Description: The patient will be examined to search for signs or symptoms of chronic venous disease (teleangiectasia, reticular veins, varicose veins, skin changes, pain, itching, heavy legs, ankle edema)

Intervention type: DIAGNOSTIC_TEST
Intervention: Echo Duplex of lower limbs
Description: The venous system of lower limbs will be checked in order to detect any vein dilation and reflux.
Study: NCT01708200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory Intervention
Description: A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
Study: NCT02783534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Description: Participants allocated to VA group will receive traditional acupuncture treatment on the Guanyuan(RN 4), bilateral Sanyinjiao(SP 6), bilateral Zigong(EX-CA1), bilateral Xuehai(SP 10). Additional points will be chosen according to TCM syndrome differentiation constitution of patients. If patients with deficient syndrome, bilateral Zusanli (ST 36) will be included. If patients with sufficiency syndrome, bilateral Diji (SP 8) will be included. The NO.16 special type of acupuncture needle (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) 5 inch lateral to the seventh thoracic spine; 2) 5 inch lateral to the eighth thoracic spine; 3) 5 inch lateral to the ninth thoracic spine; and 4) 5 inch lateral to the tenth thoracic spine.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
Study: NCT02364700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand of Hope (HOH)
Description: Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:~* warm up-passive stretch of hand in flexion and extension (5 minutes);~* setting the EMG threshold parameters for the device;~* active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)~* active practice of closing then hand (UFO Catcher game; 10 min)~* open and closing the hand (Ball and Basket game; 10 min)~* open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)~* cool down-passive stretch of hand in flexion and extension (5 minutes)
Study: NCT03123692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emeramide
Description: Lipophilic, membrane passing Metal chelator and anti oxidant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 days treatment with placebo
Study: NCT03673800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Cognitive web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Sensorial web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
Study: NCT03307109

Intervention type: OTHER
Intervention: Quality of life
Description: Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
Study: NCT00055393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 18 subjects in this randomly controlled double blind study received bupropion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 21 subjects received Placebo.
Study: NCT02626312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00751582

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplementation and nutrition education
Description: Food supplementation and nutrition education for three months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Nutrition education for children for three months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: No Nutrition Education
Study: NCT02450370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Description: Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IBS diet group
Description: Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
Study: NCT03480048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding and weight loss support
Description: The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.
Study: NCT03432676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet
Study: NCT00027534

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRICOM-CEA(6D)
Description: dendritic cells loaded with TRICOM-CEA(6D)
Study: NCT04162418

Intervention type: DEVICE
Group type: OTHER
Intervention: Temporary Spur Stent System
Description: Treatment of qualifying infrapopliteal lesions with Temporary Spur Stent System and a commercially available, limus-base drug-coated balloon
Study: NCT03954366

Intervention type: DRUG
Group type: OTHER
Intervention: Rucaparib
Description: Rucaparib 600 mg BID commencing on Day 5 until Day 23.

Intervention type: DRUG
Group type: OTHER
Intervention: Rucaparib
Description: Rucaparib 600 mg BID commencing on Day 5 until Day 23.

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Contraceptives
Description: Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
Study: NCT00904943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Capsules, 25 mg
Description: 2 x 25 mg Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Capsules, 25 mg
Description: 2 x 25 mg Capsules
Study: NCT02367898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumosity Cognitive Training
Description: adaptive online cognitive training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crossword Puzzles
Description: timed online crossword puzzles
Study: NCT04103138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedline EEG sensor placement
Description: Patients will have Sedline EEG sensor placed before or immediately after induction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sedline EEG sensor placement
Description: Patients will have Sedline EEG sensor placed before or immediately after induction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedline EEG monitoring
Description: Anaesthesia depth will be guided by EEG characteristics in addition to routine clinical parameters
Study: NCT00061087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Methylphenidate 80mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion 400mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04231578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple HOPES Guided, Internet-Delivered, Self-Help Intervention
Description: Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
Study: NCT01317472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexlansoprazole
Description: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of placebo QAM (1 hour AC) for 2 months
Study: NCT04445285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
Description: 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: Placebo of 0.9% sodium chloride every 24 hours for five (5) consecutive days; a total of 5 doses
Study: NCT04699617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dolphin 2.0
Description: The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dolphin 2.0
Description: The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures.
Study: NCT03264677

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Group 1
Description: NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Group 2
Description: NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Group 3
Description: NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
Study: NCT03692598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIA, Minimally Invasive Annuloplasty Device - Surgical
Description: Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIA, Minimally Invasive Annuloplasty Device - Percutaneous
Description: Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach
Study: NCT03363841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Description: Oral SCY-078
Study: NCT01951443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: 400mg of encapsulated Rg3-KRG

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Bran
Description: 400mg of encapsulated wheat bran
Study: NCT04538521

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The dose for a slow-released form of niacin will be 500-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 2 months. The intervention time with the full niacin dose is 8 months and subsequently total intervention time 10 months.
Study: NCT02559453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Removing dead tissue from infected wounds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Removing dead tissue from infected wounds.
Study: NCT00072462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: Tamoxifen 20mg + Anastrozole placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole 1mg + Tamoxifen placebo
Study: NCT03913936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YES portal
Description: The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YES portal
Description: The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YES portal
Description: The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician
Study: NCT03036098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified Dose on Specified Days